Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
about
Emerging therapies for acute myeloid leukemia: translating biology into the clinic.Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance.A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia.
P2860
Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@en
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@nl
type
label
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@en
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@nl
prefLabel
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@en
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@nl
P2093
P2860
P1433
P1476
Leveraging increased cytoplasm ...... dative phosphorylation in AML.
@en
P2093
Aisha Shamas-Din
ChangJiang Xu
Daina Avizonis
Dana Yehudai
Gaëlle Bridon
Marcela Gronda
Mark D Minden
Neil MacLean
Rebecca Laposa
Rose Hurren
P2860
P304
P356
10.1182/BLOOD-2016-10-741207
P407
P577
2017-03-10T00:00:00Z